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Drug resistance, difficulty in specific targeting and self-renewal properties of cancer
stem cells (CSCs) all contribute to cancer treatment failure and relapse. CSCs have
been suggested as both the seeds of the primary cancer, and the roots of chemo- and
radio-therapy resistance. The ability to precisely deliver drugs to target CSCs is an urgent
need for cancer therapy, with nanotechnology-based drug delivery system being one of
the most promising tools to achieve this in the clinic. Exosomes are cell-derived natural
nanometric vesicles that are widely distributed in body fluids and involved in multiple
disease processes, including tumorigenesis. Exosome-based nanometric vehicles have
a number of advantages: they are non-toxic, non-immunogenic, and can be engineered
to have robust delivery capacity and targeting specificity. This enables exosomes as a
powerful nanocarrier to deliver anti-cancer drugs and genes for CSC targeting therapy.
Here, we will introduce the current explorations of exosome-based delivery system in
cancer therapy, with particular focus on several exosomal engineering approaches that
have improved their efficiency and specificity for CSC targeting.
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INTRODUCTION
Cancer remains one of the leading causes of death due to the late diagnosis, poor prognosis, and
frequent occurrence of drug resistance and metastasis (Colak and Medema, 2014). Cancer stem
cells (CSCs) are a small subpopulation of immortal cancer cells, capable of long-term self-renewal,
and differentiation into heterogeneous cancer cell lineages (Bandhavkar, 2016). Although the
existing of CSCs is still controversial, recently a number of studies have identified CSCs in several
types of solid tumor, such as renal cancer, breast cancer, lung cancer, liver cancer, prostate cancer,
melanoma, and in leukemia (Huang and Rofstad, 2016). CSCs are known as the source of primary
andmetastatic cancer, and the root of chemo- and radio-therapy resistance (Sales et al., 2007; Colak
and Medema, 2014). Multiple mechanisms are involved in CSC drug resistance, including slow cell
cycle progression, drug eﬄux, enhanced DNA repair efficiency, elevated anti-apoptotic capacity,
and detoxification enzyme expression (Marhaba et al., 2008; Saha et al., 2012; Colak and Medema,
2014; Sotiropoulou et al., 2014; Lu et al., 2016). This combination of factors leads to the treatment
failure and relapse frequently observed in cancer patients. Therefore, developing novel strategies to
specifically target CSCs and overcome their drug resistance is pivotal for cancer treatment.
Wang et al. Exosomes-Based Cancer Therapies
Nanotechnology-based drug delivery systems are a variety
of synthetic nanoparticles and biological vesicles which have
biological specificity for in vivo targeting therapies. In recent
years, some synthetic nanoparticles have been employed as
vehicles to deliver therapeutic drugs to the bulk of the tumor,
and even directly target CSCs (Lu et al., 2016). Nanoparticles
also have slow drug-releasing characteristics which induce a
sustained high local drug concentration around the tumor and
an enhanced anti-cancer efficiency (Ahmad et al., 2016; Piktel
et al., 2016). As recently reviewed by Lu et al. several synthetic
nanoparticles, such as liposomes, niosomes, micelles, polymeric,
and gold nanoparticles are able to deliver anticancer drugs to
target tumor cells; this precision is made possible by their ability
to use CSC specific markers such as CD44, CD90, and CD133 to
target a specific population. Furthermore, the specificity of such
particles is enhanced by the use of different payloads which can
inhibit specific signaling pathways including Notch, Hedgehog,
and transforming growth factor-β (TGF-β) in CSCs (Lu et al.,
2016).
Biological vesicles are naturally derived from bacteria,
erythrocytes, or mammalian cells (Soltani et al., 2015). Bacterial
ghosts are obtained from chemically inactivated Gram-negative
bacterial cells after removal of their cytoplasmic contents.
Bacterial ghosts can be used as a carrier for genes, drugs,
and vaccines; however their lipopolysaccharide-caused immune
responses have limited their use in vivo (Kudela et al., 2005,
2008, 2011; Mayr et al., 2005; Paukner et al., 2005). Erythrocyte
ghosts are cytoplasmic-content free erythrocytes and have
high biocompatibility and biodegradability. They are non-toxic
and non-immunogenic with a long life span in circulation.
Unfortunately their capacity for drug loading is limited, and
deformations during transportation frequently cause unstable
encapsulation and drug leaking, limiting their clinical use
(Magnani et al., 2002; Muzykantov, 2010; Biagiotti et al., 2011;
Yousefpour and Chilkoti, 2014). Exosomes, secreted from living
cells, have been used as nanometric vehicles for therapeutic drug
and gene delivery. They are biocompatible, non-cytotoxic, low
immunogenic, simple to produce, easy to store, have a long life
span, and high cargo loading capacity (Munagala et al., 2016;
Srivastava et al., 2016; Wang et al., 2016b). These characteristics
make exosomes a promising drug carrier for cancer treatment
(Tian et al., 2013; Tang et al., 2015; Pitt et al., 2016). In this
review, we provide an overview for exosome studies with a
particular emphasis on current advances of exosome-mediated
cancer targeting therapy.
Characteristics of Exosomes
Besides engaging in cell-cell contact and directly releasing soluble
molecules through those interactions, extracellular vesicles (EVs)
derived from cells also mediate the short-range and distant
communications between cells (Hwang, 2013; Wang et al., 2014).
EVs directly shed from the plasma membrane are heterogeneous
particles with the size range of 100–1000 nm in diameter (van
der Meel et al., 2014; Vader et al., 2016). Exosomes are derived
from intracellular late endosomes but with a smaller size of 40–
100 nm. Exosome formation is initiated by early endosomes,
followed by the formation of intraluminal vesicles (ILVs) inside
the endosomes. These endosomes enclosed within mature ILVs
are called multivesicular bodies (MVBs), which can either fuse
with lysosomes for degradation and recycling, or release ILVs
as exosomes into the extracellular matrix through fusing with
plasma membrane (Théry et al., 2002; Kharaziha et al., 2012;
Klumperman and Raposo, 2014).
Exosomes contain receptors on their lipid bilayer membrane
and carry proteins, lipids, mRNAs, miRNAs, and small DNA
fragments inside to protect them from degradation (Raimondo
et al., 2011; Hwang, 2013; De Veirman et al., 2016; Wang et al.,
2016a). Exosomes can be distinguished by size and specific
surface markers including TSG101, Alix, Flotillin-1 CD63, CD9,
among other EVs (Schorey and Bhatnagar, 2008; Soltani et al.,
2015; Tang and Wong, 2015; Yu et al., 2015). Exosomes are
present widely in various cell culture-conditioned media and
body fluids including synovial fluid, saliva, urine, breast milk,
semen, and blood. Thus, several methods have been developed to
isolate exosomes from body fluids or conditioned supernatant,
including differential ultracentrifugation, density gradient
centrifugation, size exclusion chromatography, immunoaffinity
capture, and polyethylene glycol-mediated precipitation (Tauro
et al., 2012).
Function of Exosomes
As a communicator, exosomes can directly stimulate multiple
types of target cells with their membrane molecules or deliver
their contents into cells for direct influence (Camussi et al.,
2011; Raposo and Stoorvogel, 2013). Exosomes are transferred
from original cells to destination mainly through the circulating
flow and thereafter localized in target area through binding
their membrane molecules to target cell surface receptors for
long range communication. Cancer mouse models and cancer
patients have higher levels of EVs and exosomes in body fluids
(Taylor and Gercel-Taylor, 2008; Ghosh et al., 2010; Benameur
et al., 2013), implying the involvement of these particles in
cancer progression. Indeed, accumulating evidence revealed that
exosomes play a critical role in tumorigenesis. For example,
exosomes derived from mesenchymal stromal cells (MSC) or
fibroblasts directly facilitate cancer progression and induce
drug resistance in multiple myeloma, colorectal cancer, and
gastric cancer cells through delivering various miRNAs and
soluble factors into tumor cells (Roccaro et al., 2013; Wang
et al., 2014; Hu et al., 2015; Ji et al., 2015). Astrocyte-derived
exosomes transfer the miR-17∼92 cluster to suppress PTEN
gene in brain tumors (Zhang et al., 2015). Malignant cells also
secrete large amount of exosomes to promote endothelial cell
proliferation and enhance angiogenesis, which facilities tumor
progression (Umezu et al., 2014; Wang et al., 2016a). Cancer
cell-derived exosomes can also induce immunosuppression in
the tumor microenvironment (Chalmin et al., 2010; Wang
et al., 2016a). This tumor exosome-educated microenvironment
in turn facilitates tumor survival and growth. Cancer cell-
derived exosomes can preferentially fuse with the cells at their
predicted destination to form a pre-metastatic niche for tumor
metastasis (Hoshino et al., 2015). Furthermore, these cancer
cell-derived exosomes can even convert normal epithelial cells
to form tumors in mice (Melo et al., 2014). Acute myeloid
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leukemia cell-derived exosomes can deliver miR-155 into normal
hematopoietic stem and progenitor cells (HSPCs), and suppress
c-Myb expression to impair normal hematopoiesis, which in
turn facilities leukemic cell growth (Hornick et al., 2016). All
of these results underline the importance of exosome as a
messenger for cell communication during cancer progression.
Taking advantage of their natural delivery capability, exosomes
have been successfully used for drug and functional RNA delivery
vehicles in cancer treatment. Furthermore, an increasing number
of researchers have devoted their efforts to improve the capacity,
specificity, and selectivity of exosome-mediated nanodelivery in
recent years.
Advantages of Exosomes for Cancer
Therapy
Unlike synthetic nanoparticles, exosomes are more
biocompatible and biodegradable, and thus have low toxicity and
immunogenicity (Ha et al., 2016). Although other cell-derived
EVs are also biocompatible, they are bigger than exosomes and
more heterogeneous which limited their application for drug
loading and delivery. Exosomes can also be easily generated
because most cell types can produce exosomes. Exosomes are
stable in biological fluids and their small size enables exosomes
to easily escape from lung clearance and pass through the blood-
brain barrier (Kawikova and Askenase, 2015; Li et al., 2016).
Adherence and internalization of exosomes within tumor cells
is 10-times higher than liposomes of a similar size, indicating
a higher specificity of exosomes for cancer targeting (Smyth
et al., 2014). In addition, due to enhanced permeability and
retention effect, nanometric exosomes tend to accumulate in
tumor tissues containing abnormally formed blood vessels than
they do in normal tissues, thus exosomes can easily reach the
bulk of the solid tumors to increase their drug delivery efficiency.
Moreover, exosomes can be engineered with tumor-targeting
proteins, peptides, or antibodies for precise drug and therapeutic
nucleic acid delivery. Taken together, these characteristics
make exosomes one of the best candidates for cancer targeting
therapy.
Exosome Modifications for Specific
Targeting
Synthetic nanoparticle-mediated delivery has low specificity
because a very limited number of selective molecules can
be used for cell targeting. However, natural cell-produced
exosomes can recognize specific cell types via their surface
receptors. For example, exosomes with Tspan8 preferentially
bind to CD11b and CD54-postive cells (Rana et al., 2012). In
addition, researchers can engineer donor cells to obtain modified
exosomes with particular receptors for better cell recognition.
Most exosome modifications are adapted from surface display
technology which presents candidate proteins or peptides on
exosome membranes. To achieve this, researchers engineer
donor cells to express candidate proteins or peptides fused with
an exosomal membrane proteins such as lysosome-associated
membrane glycoprotein 2b (Lamp2b) and tetraspanins CD63
and CD9 (Stickney et al., 2016), which will position the
candidates on exosome’s surface. For example, dendritic cells
(DCs) were engineered to express αv integrin-specific iRGD
peptide and Lamp2b fusion protein, allowing the engineered
DCs to secret exosomes with the iRDG peptide on their surface.
These engineered exosomes have dramatically increased drug
delivery efficiency and anti-tumor effect on αv integrin-positive
breast cancer cells in a mouse model (Tian et al., 2014).
Exosomes with the neuron-specific rabies viral glycoprotein
(RVG) peptide can specifically bind to the acetylcholine
receptor on neuronal cells and selectively knockdown certain
genes in neurons, microglia, and oligodendrocytes by specific
delivery of small interfering RNA (siRNA) into those cells
(Alvarez-Erviti et al., 2011). These results indicated that
adapted exosomes can serve as a powerful tool for neural
cancer treatment. Furthermore, glycosylated peptides on
the exosome’s surface are resistant to proteasome-mediated
degradation in circulation, which enhances their stability
and even efficiency of targeted delivery (Hung and Leonard,
2015).
A recent study has used a magnet-based method to further
improve the tumor targeting specificity. Qi et al. engineered
magnetic exosomes by linking superparamagnetic-conjugated
transferrin to transferrin receptor-positive blood exosome
surfaces, and an external magnet was put on the tumor site
in vivo; this allowed the magnetic exosomes to be directed to
the target tumors cells to efficiently suppress tumor growth (Qi
et al., 2016). Although the magnetic exosomes cannot directly
target CSCs, the vast enrichment of exosomes loaded with potent
CSC targeting drugs around solid tumors can significantly
improve therapeutic efficiency and limit their side-effects by
restricting drugs on tumor site. The anti-tumor specificity
can be further improved by presenting specific anti-tumor
antibodies on exosome surface. In one study, an engineered
anti-epidermal growth factor receptor (EGFR) nanobody and
exosome anchor signal peptide glycosylphosphatidylinositol
(GPI) fusion protein were transfected to donor cells to
generate nanobody-presenting exosomes. These exosomes
were capable of directly targeted EGFR-positive tumor cells
(Kooijmans et al., 2016).
Protecting drug-loaded exosomes from liver clearance is
critical for their cancer treatment applications. Researchers
blocked scavenger receptor class A family (SR-A), a
monocyte/macrophage uptake receptor for exosomes, which
dramatically reduced exosome liver clearance and enhanced
their accumulation in tumor (Watson et al., 2016). Another
approach involving exosome-liposome hybridization was also
used to increase their specificity and stability (Sato et al., 2016).
Nakase and Futaki utilized cationic lipids as “glue” to display
pH-sensitive fusogenic peptides on exosome surfaces which
enhanced their cell membrane binding and cell uptake efficiency
of exosomes. After endocytosis, these peptides facilitated
exosome and endosome fusion, which increased the releasing of
exosomal cargos in cytoplasm (Nakase and Futaki, 2015).
Taken together, the success of these exosomal adapting
methods, as summarized in Figure 1, provide an effective CSC
treatment prospect and the combination of them will further
improve the outcome of exosome-mediated CSC targeting.
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FIGURE 1 | Summary of exosomal modifications to enhance their cancer cell targeting efficiency. Exosomes with cell/tissue-specific peptides,
tumor-specific receptors/ligands, or antibodies/nanobodies for tumor markers increase their specificity for cancer cell targeting. Exosomes displaying fluorescent
protein or chemical on the surface are used for imaging or tracking. Magnetization of exosomes elevates their accumulation around the tumor. Blockade of scavenger
receptor class A family (SR-A) reduces the clearance of exosomes by liver and increases exosome concentration in circulation and tumor. Exosome linked with
pH-sensitive peptide enhances the cytosolic delivery. Glycosylation of peptides/proteins on exosome surface increases the stability of exosomes and thus enhances
their delivery efficiency. The combination of these methods will further enhance the delivery efficacy and specificity for cancer cell targeting.
Exosome Cargo Loading for Cancer
Therapy
As a delivery system, exosomes are widely used as vehicles for
various tumor therapeutic cargos. The lipid bilayer membrane
of exosomes forms a natural protective shelter and a sustained
release capsule for various anti-cancer drugs. Various anti-
cancer drugs and cancer gene suppressors, including functional
RNAs, have been used for exosome based tumor treatment
(Seow and Wood, 2009; Camussi and Quesenberry, 2013). To
get the best tumor treatment effect, high efficacy exosome
loading methods are critical. Small membrane-permeable agent
loading can be achieved by incubating agents with exosomes
(Hood, 2016). However, to load membrane-impermeable drugs,
miRNAs, siRNAs, and small DNAs, electroporation is required to
create pores on exosome lipid bilayer membrane to allow them to
be encased within exosomes (Wahlgren et al., 2012; Hood et al.,
2014; Momen-Heravi et al., 2014). Unfortunately, even though
commercial membrane-permeable reagents such as liposomes
have been used for assisting RNA andDNA fragment loading into
exosomes, their efficiency did not satisfy most of the researchers
(Wahlgren et al., 2012; Shtam et al., 2013). Pre-overexpression
of candidate RNAs or proteins in donor cells is still considered
as the best way to generate candidate protein- and RNA-loaded
exosomes (Munoz et al., 2013).
Anticancer Agents
The best exosome cancer therapy is to have chemotherapeutic
drug-loaded exosomes specifically targeting CSCs in vivo.
Accumulating evidence has shown that exosome-mediated
chemotherapeutic delivery has much improved anti-tumor
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effects when compared to free drugs in animal tumor models.
For example, doxorubicin is a common chemotherapeutic drug
to treat hematological malignancies and many types of solid
tumors and sarcomas. Doxorubicin is fluorescent and easily
tracked, therefore it has been well studied in exosome-mediated
cancer therapy. In a colon adenocarcinoma mouse model,
exosome-delivered doxorubicin shrank tumor size much more
efficiently than did free or liposome-delivered doxorubicin (Jang
et al., 2013). Furthermore, using αv integrin-specific iRGD
peptide presenting exosomes to deliver doxorubicin dramatically
enhanced the anti-tumor effect in αv integrin-positive breast
cancer cells in animals compared to free drug administration
(Tian et al., 2014). Notably, exosome-mediated doxorubicin
delivery has dramatically reduced its cardiotoxicity, which is
considered to be the major side effect of doxorubicin in clinical
applications (Toffoli et al., 2015). This is due to the exosome-
mediated restriction of doxorubicin from crossing through
myocardial endothelial cells (Hadla et al., 2016). Due to the
advantages of this delivery system, higher concentrations of
doxorubicin can be used to treat breast and ovarian tumors while
reducing off-target effects (Hadla et al., 2016). Overall, these
studies suggest that exosome-mediated doxorubicin delivery has
great prospects for clinical application.
Paclitaxel is another widely used antimitotic
chemotherapeutic drug for various tumor therapy (Liu et al.,
2015; Bakrania et al., 2016). Paclitaxel can be loaded into
exosomes by sonication, and these loaded exosomes have 50
times more cytotoxicity than free paclitaxel for drug resistant
cancer cells in vitro. They can also dramatically block murine
Lewis lung carcinoma pulmonary metastases and reduce tumor
size in the mouse model (Kim et al., 2016). This indicates
that exosome-encapsulated paclitaxel can directly target drug
resistant CSCs. Moreover, prostate cancer cell-derived exosomes
loaded with paclitaxel also have enhanced cytotoxicity to
autologous cancer cells (Saari et al., 2015). Interestingly, drug-
pretreated donor cells can also produce drug-loaded exosomes.
For example, exosomes derived from paclitaxel-treated MSCs
exhibited a strong inhibitory effect on human pancreatic
adenocarcinoma (Pascucci et al., 2014).
Withaferin A, a potent inhibitor of angiogenesis and
cancer growth, has also been tested in exosome-mediated
delivery therapy. Either intraperitoneal or oral administration
of exosomes-loaded withaferin A showed a much stronger anti-
tumor effect compared to free drugs in human lung cancer
xenograft mouse model (Munagala et al., 2016). Exosomes
loaded with celastrol, a triterpenoid derived from plants (Chang
et al., 2003), also showed stronger anti-tumor effect compared
to free celastrol in human lung cancer cell xenograft model
(Aqil et al., 2016). Some hydrophobic anti-tumor drugs such
as curcumin, can be easily incorporated into exosome surfaces
through the lipid bilayer membrane binding (Sun et al., 2010;
Hood, 2016), which qualifies them as potential candidates for
exosome-mediated drug delivery.
Peptides and Proteins
Besides anti-cancer therapeutic drugs, exosomes can also deliver
various tumor antigens (Cho et al., 2005), apoptosis-inducing
proteins (Hall et al., 2016), nanobodies (Kooijmans et al., 2016),
deficient or mutant anti-apoptosis proteins (Aspe et al., 2014),
tumor and tissue-specific peptides (Hung and Leonard, 2015),
proteasomes (Lai et al., 2012), transferrins, and lactoferrins
(Malhotra et al., 2016) into cancer cells for targeting therapy.
DCs are widely used for T cell-mediated immunotherapy
by presenting tumor antigens to naive T cells, however this
strategy is limited by the short life span of DCs after activation
(Hermans et al., 2000). Nevertheless, researchers found that
exosomes derived from peptide-pulsed DCs, can present antigens
to T cells to induce their immune response. These DC-derived
exosomes contain MHC-peptide complexes and co-stimulatory
molecules on their membrane, which enable them to prolong
antigen presentation and boost immunization in mice compared
to antigen-presenting DCs (Luketic et al., 2007). Furthermore,
exosomes isolated from two MHC type-distinct mouse cell lines
expressing tumor antigen human mucin 1 (hMUC1), induced an
effective immune response and suppressed hMUC1-expressing
tumor cell growth in mice (Cho et al., 2005). Exosomes obtained
frommalignant mesothelioma cells were found to contain tumor
antigens; administration of these exosomes can improve the
overall survival of mesothelioma-bearing mice by activating anti-
tumor immune responses (Mahaweni et al., 2013).
Survivin, an anti-apoptotic protein, plays important roles in
multiple cancer cells to suppress apoptosis activation. Inactive
mutation survivin-T34A, impair its pro-survival activity and
induce caspase activation and apoptosis in cancer cells (Aspe
and Wall, 2010). Survivin-T34A-loaded exosomes can induce
apoptosis in various pancreatic adenocarcinoma cell lines, and
enhance their sensitivity to gemcitabine (Aspe et al., 2014).
Natural cell-derived exosomes also contain multiple activated
and functional proteins which could also facilitate the effect of
cancer therapy. One study detected high levels of all seven α and
seven β chains of the 20S proteasome and three β subunits of the
immunoproteasome in MSC-derived exosomes (Lai et al., 2012),
implicating a therapeutic potential to target cancer cells by using
exosome-delivered proteasomes.
RNAs
Abundant miRNAs are frequently detected in exosomes isolated
from either cell culture medium or bodily fluids (Yu et al.,
2015). Most of these miRNAs are functionally involved in
exosome-mediated cell-cell communication, and a subset of
them exhibited anti-cancer properties. For example, miR-
146b-enriched exosomes efficiently transfer miR-146b into
glioma cells, inhibiting their proliferation, and reducing glioma
xenograft growth in rats (Katakowski et al., 2013). EGFR-specific
binding peptide GE11 can guide Let-7a-containing exosomes
to EGFR-positive cancer cells, which dramatically inhibited
EGFR-positive human breast cancer cell growth in a xenograft
mouse model (Ohno et al., 2013). Moreover, exogenous miRNA-
143-loaded exosomes significantly reduced osteosarcoma cell
migration (Shimbo et al., 2014).
MiR-122-transfected MSCs derived from adipose tissue
can produce miR-122 loaded exosomes. These miRNA-loaded
exosomes can deliver miR-122 into hepatocellular carcinoma
cells to increase their sensitivity to chemotherapeutic agents
Frontiers in Pharmacology | www.frontiersin.org 5 January 2017 | Volume 7 | Article 533
Wang et al. Exosomes-Based Cancer Therapies
through altering genes such as cyclin G1, a disintegrin,
metalloproteinase domain-containing protein 10 (ADAM10),
and insulin-like growth factor receptor 1. Furthermore, miR-122-
loaded exosomes dramatically reduced human hepatocellular
carcinoma growth in xenograft mice (Lou et al., 2015).
MiR-134-enriched exosomes can reduce breast cancer cell
migration, invasion, and enhance their chemosensitivity through
suppressing transcription 5B, heat shock protein 90, and Bcl-
2 (O’Brien et al., 2015). MSC-derived exosomes loaded with
anti-miR-9 are able to reverse the expression of multidrug
transporters in drug resistant glioblastoma multiforme cells,
leading to an enhanced sensitivity to temozolomide treatment
(Munoz et al., 2013). In contrast, exosomes derived from
docetaxel- or adriamycin-resistant breast cancer cells contain
distinct miRNAs which can decrease the drug sensitivity in
targeted tumor cells (Chen et al., 2014; Mao et al., 2016). In this
case, drug resistance can be transferred fromCSCs to other tumor
cells. This solidifies the importance of blocking CSC-exosome
transfer as an important aspect of cancer therapy.
Using exosomes to silence genes in tumor cells by loading
them with siRNAs has been explored in recent years (Alvarez-
Erviti et al., 2011; El-Andaloussi et al., 2012). For example,
delivery of siRNA against RAD51 via exosomes dramatically
inhibited the proliferation of human breast cancer cells and
caused their death in vitro (Shtam et al., 2013). Exosome-
mediated transfer of siRNA against c-Myc can efficiently silence
c-Myc and activate the pro-apoptotic protein caspase-3 in mouse
lymphoma cells (Lunavat et al., 2016). Exosomes can also deliver
PLK-1 siRNA into bladder cancer cells to silence PLK-1, reducing
their proliferation (Greco et al., 2016).
Although exosome mediated anti-cancer effects were
observed in various tumor models (Table 1), more in vivo and
TABLE 1 | Therapeutic cargos loaded in exosomes for cancer therapy.
Cargo Origin of exosomes Target cancer type Loading method Administration
route
Outcome References
Doxorubicin Monocyte or macrophage Colon adenocarcinoma Incubation i.v. Inhibition of tumor growth Jang et al., 2013
Doxorubicin Breast cancer cell Breast and ovarian
tumor
Electroporation i.p. Inhibition of tumor growth Hadla et al., 2016
Doxorubicin Immature DC expressing
iRGD
αv integrin-positive
breast cancer
Electroporation i.v. Inhibition of tumor growth Tian et al., 2014
Doxorubicin Blood Hepatoma Incubation i.v. Inhibition of tumor growth Qi et al., 2016
Paclitaxel MSC Pancreatic
adenocarcinoma
Incubation N/A Inhibition of proliferation Pascucci et al., 2014
Paclitaxel Prostate cancer cell Prostate cancer Incubation N/A Increased cytotoxicity Saari et al., 2015
Paclitaxel Macrophage Drug resistant cells,
lung carcinoma
Incubation, sonication,
electroporation
i.n. Overcome drug resistance;
inhibition of tumor growth
Kim et al., 2016
Withaferin A Bovine milk Breast and lung cancer Incubation i.p. Inhibition of tumor growth Munagala et al., 2016
Celastrol Bovine milk Lung cancer Incubation i.g. Inhibition of tumor growth Aqil et al., 2016
hMUC1 hMUC1-expressing
carcinoma cell
hMUC1-expressing
carcinoma
Pre-overexpression i.d. Inhibition of tumor growth Cho et al., 2005
Survivin-T34A
mutant
Melanoma cell Pancreatic
adenocarcinoma
Pre-overexpression N/A Induction of apoptosis,
enhanced chemosensitivity
Aspe et al., 2014
miR-146b MSC Glioma Pre-overexpression i.t. Inhibition of tumor growth Katakowski et al., 2013
let-7a HEK293 cell expressing
GE11
EGFR-expressing
breast cancer
Pre-transfection i.v. Inhibition of tumor growth Ohno et al., 2013
miR-143 MSC Osteosarcoma Pre-transfection N/A Inhibition of migration Shimbo et al., 2014
miR-122 MSC Hepatocellular
carcinoma
Pre-overexpression i.t. Enhanced drug sensitivity,
inhibition of tumor growth
Lou et al., 2015
miR-134 Breast cancer cell Triple-negative breast
cancer
Pre-transfection N/A Reduced migration and
invasion; enhanced
chemosensitivity
O’Brien et al., 2015
Anti-miR-9 MSC Drug resistant
glioblastoma
multiforme
Pre-overexpression N/A Enhanced chemosensitivity Munoz et al., 2013
RAD51 siRNA Breast cancer cell Breast cancer Transfection,
electroporation
N/A Inhibition of proliferation;
induction of apoptosis
Shtam et al., 2013
c-Myc siRNA Monocytic cell Lymphoma Electroporation N/A Induction of apoptosis Lunavat et al., 2016
PLK-1 siRNA HEK293 cell or MSC Bladder cancer Electroporation N/A Inhibition of proliferation;
induction of apoptosis
Greco et al., 2016
DC, dendritic cell; MSC mesenchymal stromal cell; hMUC1, human mucin 1; HEK293, human embryonic kidney293; EGFR, epidermal growth factor receptor; PLK-1, polo-like kinase
1; i.v., intravenous; i.p., intraperitoneal; i.n., intranasal; i.g., intragastrical; i.d., intradermal; i.t., intratumoral; N/A, not applicable.
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clinical evidence for different kinds of tumors are still needed.
Therefore, developing more specific CSC targeting exosomes will
be a promising cancer therapy strategy in the future.
Opportunities for Exosome-Mediated CSC
Targeting Delivery
As described above, exosome-mediated cancer therapy has been
widely studied and proved to have great potential for CSC
targeting. Using the identified CSC features, we can improve
current exosome engineering techniques to allow more precise
targeting (Figure 2). The cell surface marker CD44 is highly
expressed in high tumorigenic and metastatic hepatocellular
CSCs, and Anti-CD44 antibody-coated liposomes can deliver
doxorubicin directly to CSCs positive for this marker (Arabi
et al., 2015). Interestingly, the anti-CD44 antibody itself can
induce the apoptosis of CD90+ hepatocellular carcinoma stem
cells (Yang et al., 2008). Conceivably, an anti-CD44 antibody-
coated exosome could directly induce CSC death, along with
their drug delivery role. Therefore, other CSC markers like
CD133, CD24, epithelial cell adhesion molecule (EpCAM), and
CD200, can also be used as targeting candidates to improve
the exosome-mediated CSC targeting efficiency. Since CSC cell
surface markers can vary from tumor to tumor, in the future
multiple-antibody coated exosomes will need to be engineered
to improve their CSC targeting efficiency and to reduce the side
effect on normal cells; this because normal cells may present one
CSC cell surface marker, but not several of them simultaneously.
In addition to targeting cell surface markers, exosomes can also
target CSC specific signal pathways. For example, Wnt, Notch,
Hippo, Hedgehog, NF-κB, and TGF-β pathways are crucial to
maintain the CSC capacities such as self-renewal, differentiation,
tumor initiation, and drug resistance (Dandawate et al., 2016;
Huang and Rofstad, 2016; Rinkenbaugh and Baldwin, 2016).
Using exosomes loaded with inhibitors, miRNAs, or siRNAs to
target these pathways can be considered an alternative way to
achieve CSC targeting.
Clinical Trials of Exosomes in Cancer
Therapy
Since many promising results have been achieved in vitro and in
animal models, using exosomes for CSC targeting is considered
to be one of the most hopeful approaches for cancer treatment.
Notably, some clinical trials have already made important
achievements (Table 2). As showed in a phase I trial, metastatic
melanoma patients were intradermally and subcutaneously given
exosomes obtained from autologous DCs and loaded with the
MAGE tumor antigens for 4 weeks. Although no significant
outcome has been observed yet, the safety and feasibility of
exosome administration have been confirmed in these patients
(Escudier et al., 2005). Another phase I trial showed that the
FIGURE 2 | Schematic illustration of exosomal modification and cargo loading for CSC targeting. Exosomes displaying CSC-specific peptides, magnetic
beads, CSC-specific receptor/ligand, and antibodies for CSC surface maker will significantly enhance the accumulation of exosomes in tumor and increase their CSC
targeting specificity. The therapeutic exosome cargos, including chemotherapeutics, inhibitors of CSC signaling, siRNA/miRNA targeting oncoprotien and CSC
signaling, pro-apoptotic proteins, and proteasome will elevate the efficiency of killing CSCs. Exosomes present CSC-specific antigens to T cells and activate T cells for
anti-CSC immunization. Modified exosome carrying therapeutic cargos can pass through the blood-brain barrier and facilitate CSC targeting in brain tumor.
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TABLE 2 | Human clinical trials of exosomes in cancer therapy.
Cargo Origin of exosomes Cancer type Phase Results References
Tumor antigenic
peptides
Dendritic cells pulsed with
antigenic peptides
Melanoma I Proof of Feasibility and Safety; toxicity < Grade II Escudier et al., 2005
Tumor antigenic
peptides
Dendritic cells pulsed with
antigenic peptides
Non-small lung cancer I Proof of feasibility and Safety; toxicity < Grade I-II,
9/13 completed therapy
Morse et al., 2005
Tumor antigenic
peptides
IFN-γ-matured dendritic cells
pulsed with antigenic peptides
Advanced non-small
cell lung cancer
II 32% of participants experienced stabilization for
more than 4 months; boosted NK cell-mediated
anti-tumor immunity
Besse et al., 2016
Autologous ascites Colon Cancer I Proof of feasibility and Safety; Toxicity < Grade I–II Dai et al., 2008
Curcumin Plant Colon Cancer I Ongoing NCT01294072
immune response was activated and disease progression was
slowed in a small number of exosome-treated non-small cell
lung cancer patients (Morse et al., 2005). Evidence showed that
exosomes with interferon-γ (IFN-γ) treatment have enhanced
immune activation and tumor suppression effects (Viaud et al.,
2011). Based on these phase I and preclinical results, a phase
II trial was performed which showed that IFN-γ-DC-derived
exosomes were capable of boosting NK cell-mediated anti-tumor
immunity in advanced non-small cell lung cancer patients. Thirty
two percent of participants experienced stabilization for more
than 4 months, although the primary endpoint has not yet
been reached (Besse et al., 2016). An ascite-derived exosomes
combined with GM-CSF treatment was revealed in a phase
I clinical trial for colorectal cancer, showing the induction
of beneficial tumor-specific antitumor cytotoxic T lymphocyte
response (Dai et al., 2008). Another ongoing phase I clinical
trial is trying to determine the ability of plant exosomes to
deliver curcumin to colon tumor (NCT01294072, http://www.
clinicaltrials.gov).
Overall, multiple clinical trials are ongoing. In the future,
standardization of the exosome isolation, storage, cargo loading,
quality control, and efficacy evaluation procedures will be
necessary for clinical trial and treatment.
Perspective
Exosomes, as a natural nanocarrier, have great potential as a
cancer therapy; however, more work is still needed, especially for
in vivo studies and clinical trials. Exosomes derived from cancer
cells carry functional cargos which directly or indirectly facilitate
tumor cell growth (Wang et al., 2014, 2015, 2016a). Therefore,
how to identify and remove those tumor supporting components
from exosomes is critical for exosome-mediated cancer therapy,
and efforts to improve the cargo loading efficiency of exosomes
should be a focus going forward. Currently, electroporation
is still the best way for loading siRNAs, miRNAs, and small
DNA fragments into exosomes, unfortunately this process often
induces their aggregation and degradation (Kooijmans et al.,
2013). An improved method for sensitive cargo loading, such
as siRNA and mRNA, is urgently needed. Using functional
exosomes to facilitate immunotherapy is a promising therapy for
cancer treatment, since exosomes are more stable than activated
antigen presenting cells and can be easily engineered. These
features result in exosome-based delivery systems being one of
the best approaches for CSC targeting therapy.
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